SCHEMBL9935958

SCHEMBL9935958

NC(=O)c1c(N)n(C(=O)c2ccc(F)cc2)c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
MAPT P10636 3/20 0.54
HTT P42858 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 1/20 0.52
NOD1 Q9Y239 1/20 0.52
AGTR1 P30556 2/20 0.46
P2RX4 Q99571 1/20 0.44
MGAM O43451 1/20 0.42
AMY1A P0DUB6 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28222168 0.76 LMNA (0.49) LMNAMAPTHTTKMT2AMEN1
SCHEMBL8023046 0.74 MAPT (0.74) LMNAMAPTHTTKMT2AMEN1
SCHEMBL20159060 0.73 P2RX4 (0.56) LMNAMAPTHTTKMT2AMEN1
SCHEMBL579598 0.72 USP14 (0.46) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL4639305 0.71 MAPT (0.69) LMNAMAPTHTTKMT2AMEN1
SCHEMBL9884403 0.71 EGFR (0.54) LMNAMAPTHTTKMT2AMEN1
SCHEMBL27715633 0.71 LMNA (1.00) LMNAMAPTHTTKMT2AMEN1
SCHEMBL28222169 0.70 NPC1 (0.59) LMNAMAPTHTTKMT2AMEN1
SCHEMBL3205310 0.67 CYP19A1 (0.54) LMNAMAPTHTTKMT2AMEN1
SCHEMBL24547737 0.67 LMNA (0.50) LMNAMAPTHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3304088-B1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE ELECTROPHORETICS LTD (GB) 2025-07-30 EP claimed
EP-3304088-A1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE Electrophoretics Limited (GB) 2018-04-11 EP claimed
US-9763947-B2 Casein kinase 1delta (CK1delta) inhibitors ELECTROPHORETICS LIMITED (GB) 2017-09-19 US claimed
WO-2016189163-A1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE ELECTROPHORETICS LIMITED (GB) 2016-12-01 WO claimed
CN-105920010-A Casein Kinase 1delta (ck 1delta) Inhibitors 电泳有限公司 2016-09-07 CN claimed
CN-103298460-B Casein kinase 1(CK1) inhibitors ELECTROPHORETICS LTD. (GB) 2016-06-01 CN claimed
US-20160058745-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2016-03-03 US claimed
EP-2651404-B1 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS ELECTROPHORETICS LTD (GB) 2015-10-14 EP claimed
US-20140018540-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED 2014-01-16 US claimed
EP-2651404-A2 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP claimed
CN-103298460-A Casein kinase 1 delta (CK1 delta) inhibitors ELECTROPHORETICS LTD 2013-09-11 CN claimed
WO-2012080727-A2 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO claimed
US-20260091025-A1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE ELECTROPHORETICS LIMITED (GB) 2026-04-02 US disclosed
EP-4663754-A2 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE Electrophoretics Limited (GB) 2025-12-17 EP disclosed
US-12419871-B2 Biomolecules involved in Alzheimer's disease ELECTROPHORETICS LIMITED (GB) 2025-09-23 US disclosed
EP-3304088-B1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE ELECTROPHORETICS LTD (GB) 2025-07-30 EP disclosed
US-20140018540-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED 2014-01-16 US disclosed
EP-2651404-A2 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS Electrophoretics Limited (GB) 2013-10-23 EP disclosed
CN-103298460-A Casein kinase 1 delta (CK1 delta) inhibitors ELECTROPHORETICS LTD 2013-09-11 CN disclosed
WO-2012080727-A2 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018540-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS CSNK1G1, CSNK1A1, CSNK1D LMNA 1292/4885MAPT 56/4885HTT 1548/4885
US-20260091025-A1 BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE PYGB, PACSIN2, PPP3CA LMNA 2088/4885MAPT 25/4885HTT 2618/4885
US-20160058745-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS CSNK1A1, CSNK1G1, CSNK1D LMNA 1197/4885MAPT 60/4885HTT 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.